Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

EOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... US demand for specialty biocides is forecast to ... 2018. In volume terms, demand is projected to increase ... the same period. A strong rebound in construction expenditures ... and paint and coatings markets, while growth in consumer ...
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "Global and Chinese Microcrystalline Cellulose Industry Report ... The Global and Chinese Microcrystalline Cellulose Industry Report 2014 ... state of the global microcrystalline cellulose industry with a ... provides a basic overview of the industry including definitions, ...
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... industry will face many serious issues over the next ... rigors of engineering better biofuels and bioproducts. But few ... the 20,000 convention visitors at BIO '06. , ... ,A walk-through in Chicago's massive McCormick Place demonstrates just ...
... and discovery. From medicine to manufacturing, some of the ... our state. Today, amid a revolution in biotechnology and ... ,From developing innovative new sources of renewable energy that ... oil to working to find cures to Parkinson's, Alzheimer's ...
... Chicago The biotechnology industry has a job to ... luncheon attended by thousands at the BIO Chicago conference. , ... infectious diseases, guard against pandemics, create crops that can feed ... such as ethanol, and confront global warming head on. , ...
Cached Biology Technology:My-oh, it's BIO! Where sales hype and science collide 2Making Wisconsin the biotechnology leader 2Making Wisconsin the biotechnology leader 3Clinton says world needs biofuels, GM crops, and more answers 2Clinton says world needs biofuels, GM crops, and more answers 3
(Date:9/22/2014)... in recent years has been identified as the plant,s ... aroma also summons beneficial insects to the rescue. , ... the environment via the emission of volatile organic compounds, ... wasps to come to the plant that is being ... Dr. Michael Kolomiets, Texas A&M AgriLife Research plant pathologist ...
(Date:9/22/2014)... in a plant,s biological clock one that modulates ... , Transcription factors, or genetic switches, drive gene expression ... light, rain, soil quality, or even animals grazing on ... one, called FBH1, that reacts to temperature tweaking ... keeping it on a consistent track. , "Temperature helps ...
(Date:9/22/2014)... CITY (September 22, 2014)The Brain & Behavior ... award of NARSAD Young Investigator Grants valued ... of the world,s most promising young scientists. ... groundbreaking neurobiological research will seek to identify ... for psychiatric disorders that affect one in ...
Breaking Biology News(10 mins):Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Genetic switch regulates a plant's internal clock based on temperature 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... to save a species in the 21st century? The specter ... as 35 percent, has some scientists and managers considering taking ... relocation (MR) is literally the physical relocation of endangered or ... and foreign geographical climes. It addresses the concern that climate ...
... at the National Institutes of Health have found that ... cell energy metabolism appear to increase the risk for ... the enzyme phosphodiesterase 11A (PDE11A), which helps regulate a ... studies by NIH researchers have linked genetic variations that ...
... greatly from our real-life partner, according to new research from ... France. The research found that our actual partners are of ... we would ideally choose. The study, which was ... PLoS ONE , found that most men and women express ...
Cached Biology News:Climate change forcing a 'move it or lose it' approach to species conservation? 2Climate change forcing a 'move it or lose it' approach to species conservation? 3Gene variations that alter key enzyme linked to prostate cancer 2Study shows real partners are no match for ideal mate 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: